Coronavirus: dermatology update
In response to the coronavirus (COVID-19) outbreak, please read our advice and information.
Recent and ongoing research projects include trials of a new anti-IgE biologic for chronic spontaneous urticaria (ligelizumab), a topical mast cell inhibitor cream and a study of KIT mutations in peripheral blood of children.
Multicentre studies for novel treatments in chronic urticaria and mastocytosis are planned for 2019.
Find out more about our open and completed clinical trials.